Could a 30-Minute infusion be as safe as an hour for kids with IBD?

NCT ID NCT06839820

Ongoing Symptom relief Sponsor: University Hospital, Akershus Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares giving the drug infliximab over 30 minutes versus the standard 60 minutes in children with inflammatory bowel disease (IBD). The goal is to see if the shorter infusion causes just as few allergic reactions and improves patient and nurse satisfaction. Sixty children aged 1-17 who have already had at least 5 infliximab infusions will each receive 8 infusions, alternating between the two speeds.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: infliximab
What this could lead to: If successful, this could allow children with IBD to receive infliximab infusions in half the usual time, reducing clinic visits and improving quality of life.
What could go wrong: This is a small, early-stage study with only 60 participants. Faster infusions may still cause more allergic reactions, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IBD (INFLAMMATORY BOWEL DISEASE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

inflammatory bowel disease irritable bowel syndrome Patient Satisfaction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IBD (INFLAMMATORY BOWEL DISEASE) INFLIXIMAB INFUSION PATIENT SATISFACTION

Contacts and locations

Locations

Akershus University Hospital

Lørenskog, 1478, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.